Emerging CRISPR-Cas Platforms for Rapid and Field-Deployable Detection of Multidrug-Resistant Microbes

Q: How many days will it take for my paper to be published?

The review time for papers is not fixed. However, if the paper is accepted and the author completes the processing charges formalities, the paper will be published within a few working days.

Q: I would like to receive a hard copy of the journal materials. Are there any additional charges?

You can log in to the author portal and pay 500 INR to receive the hard copy materials.

Suman Mondal; NA; NA; NA

Emerging CRISPR-Cas Platforms for Rapid and Field-Deployable Detection of Multidrug-Resistant Microbes

Authors: Suman Mondal, NA, NA, NA

Unique Paper ID: 182902
Volume: 12
Issue: 2
PageNo: 3517-3527

Keywords: CRISPR-Cas systems multidrug-resistant microbes antimicrobial resistance molecular diagnostics.

Abstract:
The emergence and global spread of multidrug-resistant (MDR) microbes present a critical challenge to infectious disease management, necessitating rapid, accurate, and decentralized diagnostic solutions. Traditional microbiological methods remain constrained by prolonged turnaround times, infrastructure dependence, and suboptimal sensitivity. CRISPR-Cas systems, originally discovered as bacterial immune mechanisms, have since been repurposed into next-generation diagnostic platforms with remarkable specificity and versatility. This review explores the diagnostic capabilities of emerging CRISPR-based technologies such as SHERLOCK, DETECTR, and Cas12/13/14 systems, with a focus on their application in MDR pathogen detection. Particular attention is given to the ability of these platforms to target resistance genes in clinical and environmental samples, often without nucleic acid amplification. The integration of CRISPR diagnostics with isothermal amplification, microfluidic chips, and smartphone-compatible formats is also examined for field-deployable use. Current challenges including off-target effects, assay standardization, and regulatory hurdles are discussed alongside prospective solutions for broad clinical implementation against the rising AMR threat.

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 12
Issue: 2
PageNo: 3517-3527

Emerging CRISPR-Cas Platforms for Rapid and Field-Deployable Detection of Multidrug-Resistant Microbes

Available:https://ijirt.org/article?manuscript=182902

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now